红花黄色素注射液联合依达拉奉对急性脑梗死血液流变学及神经功能的影响
|
摘要
目的:探究红花黄色素注射液联合依达拉奉对急性脑梗死患者血液流变学及神经功能影响。方法:选取2016年2月—2018年1月收治的120例急性脑梗死患者作为研究对象,采取随机双盲法将所有患者分为观察组以及对照组,对照组所有患者(60例)均给予常规治疗+依达拉奉治疗,观察组所有患者(60例)则对照组患者治疗基础上联合红花黄色素注射液治疗,对比两组患者临床治疗效果、治疗前后患者神经功能缺损评分(NIHSS)及日常生活能力评分(Barthel)、全血高切黏度(HSV)、全血低切黏度(LSV)、血浆黏度(PSV)、红细胞比容(HCT)、红细胞沉降率(ESR)等血液流变学指标变化情况及低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)、甘油三酯(TG)等血脂指标变化情况、患者并发症率及药物不良反应率。结果:观察组患者治疗后总有效率高达96.67%,对照组为86.67%,观察组有效率显著高于对照组,P<0.05,差异具有统计学意义;治疗前两组患者NIHSS及Barthel评分、HSV、LSV、PSV、HCT、ESR等血液流变学指标水平、LDL-C、HDL-C、TC、TG等血脂水平均相当,P>0.05,差异无统计学意义,治疗后两组患者NIHSS及Barthel评分、HSV、LSV、PSV、HCT、ESR等血液流变学指标水平、LDL-C、HDL-C、TC、TG等血脂水平均改善,观察组改善程度优于对照组,P<0.05,差异具有统计学意义。观察组患者并发症率为1.67%,低于对照组11.67%,P<0.05,差异具有统计学意义;观察组患者药物不良反应率为3.33%,与对照组不良反应率(1.67%)相当,P>0.05,差异无统计学意义。结论:红花黄色素注射液联合依达拉奉治疗急性脑梗死可显著提升患者临床治疗效果,改善患者神经功能及血流、血脂状况,提升患者日常生活能力,降低并发症率,且药物不良反应率低,安全性高,值得临床推广以及应用。
Objective:To explore the effects of safflower yellow injection on hemorheology and neurological function in patients with acute cerebral infarction.Methods:From February 2016 to January 2018, 120 cases of acute cerebral infarction patients as the research object, by the randomized double blind method, were divided into observation group and control group. The control group's patients(60 cases) were given routine therapy+ inedaravone and the observation group's patients(60 cases added safflower yellow injection. We compared two groups' clinical treatment, nerve function defect score(NIHSS) and daily life ability score(Barthel), whole blood high shear viscosity(HSV), whole blood low shear viscosity(LSV), plasma viscosity(PSV), erythrocyte hematocrit(HCT), erythrocyte sedimentation rate(ESR) and changes of hemorheology indexes such as low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), total cholesterol(TC), triglyceride(TG) and so on, complication rate and the rate of adverse drug reactions.Results:After treatment, the total effective rate of the observation group was 96.67%, and the control group's was 86.67%. The effective rate of observation group was significantly higher than that in the control group(P<0.05) and the difference was statistically significant. Two groups' NIHSS and Barthel score, HSV, LSV, PSV eindhoven, HCT, ESR hemorheology indexes such as LDL-C, TC, TG, HDL-C levels before treatment werenot signficant. After treatment,the two groups' NIHSS and Barthel score, HSV, LSV, PSV, HCT, ESR hemorheology indexes such as LDL-C, HDL-C,TC, TGlevels were improved, and the observation group'swere better than those of the control group(P<0.05) and the difference was statistically significant. The complication rate was 1.67% in the observation group, which was less than 11.67% in the control group(P<0.05) and the difference was statistically significant. The adverse drug reaction rate was 3.33% in the observation group, which was comparable to the adverse reaction rate(1.67%) in the control group, and the difference was not statistically significant(P>0.05).Conclusion:Safflower yellow injection combined with inedaravone in treatment of patients with acute cerebral infarction can significantly improve the clinical effect,patients' nerve function and blood flow, blood lipid and daily life ability, and decrease the rate of complications, with low adverse drug reaction rate and high security, worthy of clinical promotion and application.
Objective:To explore the effects of safflower yellow injection on hemorheology and neurological function in patients with acute cerebral infarction.Methods:From February 2016 to January 2018, 120 cases of acute cerebral infarction patients as the research object, by the randomized double blind method, were divided into observation group and control group. The control group's patients(60 cases) were given routine therapy+ inedaravone and the observation group's patients(60 cases added safflower yellow injection. We compared two groups' clinical treatment, nerve function defect score(NIHSS) and daily life ability score(Barthel), whole blood high shear viscosity(HSV), whole blood low shear viscosity(LSV), plasma viscosity(PSV), erythrocyte hematocrit(HCT), erythrocyte sedimentation rate(ESR) and changes of hemorheology indexes such as low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), total cholesterol(TC), triglyceride(TG) and so on, complication rate and the rate of adverse drug reactions.Results:After treatment, the total effective rate of the observation group was 96.67%, and the control group's was 86.67%. The effective rate of observation group was significantly higher than that in the control group(P<0.05) and the difference was statistically significant. Two groups' NIHSS and Barthel score, HSV, LSV, PSV eindhoven, HCT, ESR hemorheology indexes such as LDL-C, TC, TG, HDL-C levels before treatment werenot signficant. After treatment,the two groups' NIHSS and Barthel score, HSV, LSV, PSV, HCT, ESR hemorheology indexes such as LDL-C, HDL-C,TC, TGlevels were improved, and the observation group'swere better than those of the control group(P<0.05) and the difference was statistically significant. The complication rate was 1.67% in the observation group, which was less than 11.67% in the control group(P<0.05) and the difference was statistically significant. The adverse drug reaction rate was 3.33% in the observation group, which was comparable to the adverse reaction rate(1.67%) in the control group, and the difference was not statistically significant(P>0.05).Conclusion:Safflower yellow injection combined with inedaravone in treatment of patients with acute cerebral infarction can significantly improve the clinical effect,patients' nerve function and blood flow, blood lipid and daily life ability, and decrease the rate of complications, with low adverse drug reaction rate and high security, worthy of clinical promotion and application.
引文
[1] 李娇红,程锦楠,李作孝,等.丹参川芎嗪注射液对急性脑梗死患者血清HIF-1α、Caspase-3及血尿酸水平影响研究[J].中华中医药学刊,2018,36(2):435-437.
[2] 王鹏,林涛,车海江,等.联合药物方案辅助治疗对脑动脉瘤栓塞术后脑血管痉挛患者GCS评分、生活质量及脑梗死发生率影响[J].临床军医杂志,2017,45(2):200-202.
[3] 王晓宇,朱彩花,楼滟.血栓通联合丁苯酞对老年急性脑梗死血清中Fibulin-5、BDNF及S100B的影响[J].中华中医药学刊,2018,36(1):235-238.
[4] 吴松,王大明,金肇权.急性脑梗死患者血清C反应蛋白/脂联素和T细胞亚群与临床预后及神经功能的关系[J].东南大学学报(医学版),2018,37(1):101-106.
[5] 高娟,杜冬青.针灸联合西医治疗对急性期脑梗死患者足底压力等生物力学参数变化的观察[J].针灸临床杂志,2017,33(9):24-27.
[6] 陈杰,田慧军.针灸联合氟西汀对急性脑梗死伴抑郁患者神经功能、负性情绪及免疫功能的影响[J].针灸临床杂志,2017,33(7):32-35.
[7] 杨锐,陈晓荣,刘安陆,等.DWI联合ADC在原发性中枢神经系统淋巴瘤与急性脑梗死鉴别诊断中的价值[J].现代医学,2018,46(1):23-26.
[8] 胡重灵,杨新玲,毛德强,等.急性脑梗死患者血清泛素羧基末端水解酶-Ⅰ和胶质纤维酸性蛋白的表达及其临床意义[J].中南大学学报(医学版),2017,42(3):284-290.
[9] 刘雪芳,秦雪颖,李继来,等.短暂性脑缺血发作患者颅内血管狭窄程度和ABCD2评分与近期预后的关系研究[J].川北医学院学报,2017,32(2):221-223.
[10] 徐霁华,秦伟,袁俊亮,等.超早期应用重组组织型纤溶酶原激活剂静脉溶栓治疗超高龄患者脑梗死[J].山东医药,2017,57(15):68-70.
[11] 刘圣根,胡小花,陈燕,等.外敷黑虎膏联合常规疗法治疗脑梗死效果及机制[J].中国老年学杂志,2017,37(14):3453-3455.
[12] 肖斌.低频重复经颅磁刺激联合丁苯酞治疗对脑梗死患者神经及运动功能的影响[J].中国实用神经疾病杂志,2017,20(4):59-61.
[13] 杜岩,曲华.负荷量氯吡格雷联合阿司匹林治疗再发性脑梗死的临床研究[J].中国医科大学学报,2017,46(9):836-838,843.
[14] 耿松,朱毅平,郭萍,等.氟西汀联合重复经颅磁刺激治疗无症状脑梗死患者老年抑郁的疗效观察[J].中华物理医学与康复杂志,2017,39(9):683-685.
[15] 张合亮,刘美利,孙刚,等.Solumbra血管内再通技术治疗急性大动脉闭塞性脑梗死[J].中华老年医学杂志,2018,37(2):148-153.
[16] 刘悦,范承哲,王力,等.经皮血管内成形及支架置入术治疗伴重度颈动脉狭窄脑梗死的短期疗效评价[J].中华神经医学杂志,2017,16(7):688-691.
[17] 程艳伟,于敏敏,张菲菲,等.恶性肿瘤并发脑梗死研究进展[J].中国脑血管病杂志,2017,14(12):655-659.
[18] 刘帮健,曲忠森,赵玉武,等.B型钠尿肽对心房颤动合并脑梗死急性期抗栓治疗选择的意义[J].上海交通大学学报(医学版),2017,37(1):85-88.
[19] 吴钢,阳洪,潘丽雅,等.重复经颅磁刺激治疗左半球脑梗死失语的效果及作用机制[J].山东医药,2017,57(37):65-67.
[20] 郭婷婷,黄照,王玉洁,等.抗血小板治疗后血小板高反应性与急性非心源性脑梗死早期神经功能恶化的关系[J].中华老年心脑血管病杂志,2017,19(9):926-929.
[21] 李鹤婷,徐艳红,杨嘉君,等.rt-PA静脉溶栓脑梗死患者治疗前血清胆红素、尿酸水平与早期神经功能改善情况及预后的关系[J].山东医药,2017,57(27):43-45.
[22] 王林林.红花黄色素联合参芎葡萄糖注射液治疗老年急性脑梗死[J].内蒙古医学杂志,2017,49(5):618-619.
[23] 吴颖.红花黄色素注射液治疗腔隙性脑梗死的疗效观察[J].当代医学,2017,23(9):16-17.
[24] 李佳利,李小华.注射用红花黄色素治疗脑梗死的临床疗效评价[J].大家健康(下旬版),2017,11(5):127.
[25] 朱静.依达拉奉与巴曲酶联用治疗脑梗死的疗效评价[J].河北医药,2017,39(10):1536-1538.
[26] 姚涛,湛彦强,胡丹,等.依达拉奉联合阿托伐他汀治疗脑梗死的疗效分析[J].西南国防医药,2017,27(5):454-456.
[27] 尹魁明,肖爱玲.低分子肝素联合依达拉奉治疗进展性脑梗死的临床疗效及安全性[J].中国老年学杂志,2017,37(1):106-108.
[2] 王鹏,林涛,车海江,等.联合药物方案辅助治疗对脑动脉瘤栓塞术后脑血管痉挛患者GCS评分、生活质量及脑梗死发生率影响[J].临床军医杂志,2017,45(2):200-202.
[3] 王晓宇,朱彩花,楼滟.血栓通联合丁苯酞对老年急性脑梗死血清中Fibulin-5、BDNF及S100B的影响[J].中华中医药学刊,2018,36(1):235-238.
[4] 吴松,王大明,金肇权.急性脑梗死患者血清C反应蛋白/脂联素和T细胞亚群与临床预后及神经功能的关系[J].东南大学学报(医学版),2018,37(1):101-106.
[5] 高娟,杜冬青.针灸联合西医治疗对急性期脑梗死患者足底压力等生物力学参数变化的观察[J].针灸临床杂志,2017,33(9):24-27.
[6] 陈杰,田慧军.针灸联合氟西汀对急性脑梗死伴抑郁患者神经功能、负性情绪及免疫功能的影响[J].针灸临床杂志,2017,33(7):32-35.
[7] 杨锐,陈晓荣,刘安陆,等.DWI联合ADC在原发性中枢神经系统淋巴瘤与急性脑梗死鉴别诊断中的价值[J].现代医学,2018,46(1):23-26.
[8] 胡重灵,杨新玲,毛德强,等.急性脑梗死患者血清泛素羧基末端水解酶-Ⅰ和胶质纤维酸性蛋白的表达及其临床意义[J].中南大学学报(医学版),2017,42(3):284-290.
[9] 刘雪芳,秦雪颖,李继来,等.短暂性脑缺血发作患者颅内血管狭窄程度和ABCD2评分与近期预后的关系研究[J].川北医学院学报,2017,32(2):221-223.
[10] 徐霁华,秦伟,袁俊亮,等.超早期应用重组组织型纤溶酶原激活剂静脉溶栓治疗超高龄患者脑梗死[J].山东医药,2017,57(15):68-70.
[11] 刘圣根,胡小花,陈燕,等.外敷黑虎膏联合常规疗法治疗脑梗死效果及机制[J].中国老年学杂志,2017,37(14):3453-3455.
[12] 肖斌.低频重复经颅磁刺激联合丁苯酞治疗对脑梗死患者神经及运动功能的影响[J].中国实用神经疾病杂志,2017,20(4):59-61.
[13] 杜岩,曲华.负荷量氯吡格雷联合阿司匹林治疗再发性脑梗死的临床研究[J].中国医科大学学报,2017,46(9):836-838,843.
[14] 耿松,朱毅平,郭萍,等.氟西汀联合重复经颅磁刺激治疗无症状脑梗死患者老年抑郁的疗效观察[J].中华物理医学与康复杂志,2017,39(9):683-685.
[15] 张合亮,刘美利,孙刚,等.Solumbra血管内再通技术治疗急性大动脉闭塞性脑梗死[J].中华老年医学杂志,2018,37(2):148-153.
[16] 刘悦,范承哲,王力,等.经皮血管内成形及支架置入术治疗伴重度颈动脉狭窄脑梗死的短期疗效评价[J].中华神经医学杂志,2017,16(7):688-691.
[17] 程艳伟,于敏敏,张菲菲,等.恶性肿瘤并发脑梗死研究进展[J].中国脑血管病杂志,2017,14(12):655-659.
[18] 刘帮健,曲忠森,赵玉武,等.B型钠尿肽对心房颤动合并脑梗死急性期抗栓治疗选择的意义[J].上海交通大学学报(医学版),2017,37(1):85-88.
[19] 吴钢,阳洪,潘丽雅,等.重复经颅磁刺激治疗左半球脑梗死失语的效果及作用机制[J].山东医药,2017,57(37):65-67.
[20] 郭婷婷,黄照,王玉洁,等.抗血小板治疗后血小板高反应性与急性非心源性脑梗死早期神经功能恶化的关系[J].中华老年心脑血管病杂志,2017,19(9):926-929.
[21] 李鹤婷,徐艳红,杨嘉君,等.rt-PA静脉溶栓脑梗死患者治疗前血清胆红素、尿酸水平与早期神经功能改善情况及预后的关系[J].山东医药,2017,57(27):43-45.
[22] 王林林.红花黄色素联合参芎葡萄糖注射液治疗老年急性脑梗死[J].内蒙古医学杂志,2017,49(5):618-619.
[23] 吴颖.红花黄色素注射液治疗腔隙性脑梗死的疗效观察[J].当代医学,2017,23(9):16-17.
[24] 李佳利,李小华.注射用红花黄色素治疗脑梗死的临床疗效评价[J].大家健康(下旬版),2017,11(5):127.
[25] 朱静.依达拉奉与巴曲酶联用治疗脑梗死的疗效评价[J].河北医药,2017,39(10):1536-1538.
[26] 姚涛,湛彦强,胡丹,等.依达拉奉联合阿托伐他汀治疗脑梗死的疗效分析[J].西南国防医药,2017,27(5):454-456.
[27] 尹魁明,肖爱玲.低分子肝素联合依达拉奉治疗进展性脑梗死的临床疗效及安全性[J].中国老年学杂志,2017,37(1):106-108.